Summary:
- Diakonos Oncology Corp. closed a $20m private placement of Simple Agreements for Future Equity (SAFE) to develop immunotherapies for aggressive cancers.
- New investors include Baylor College of Medicine and the Brain Tumor Investment Fund, with plans to accelerate Phase 2 glioblastoma trial for dubodencel.
- Dubodencel is a first-in-class dendritic cell therapy combining tumor lysate and mRNA for late-stage cancer treatment.
Article:
Diakonos Oncology Corp. Secures $20m Funding for Innovative Cancer Immunotherapies
Diakonos Oncology Corp., a Houston-based biotechnology company, recently announced the successful closure of a $20 million private placement of Simple Agreements for Future Equity (SAFE). The company specializes in developing a new generation of immunotherapies aimed at treating challenging and aggressive cancers.
The funding round saw participation from new investors such as Baylor College of Medicine (BCM) and the Brain Tumor Investment Fund (BTIF), along with support from existing shareholders including CEO Mike Wicks. BCM will also provide valuable in-kind services towards the company’s pre-clinical and clinical development programs.
With the newly secured funds, Diakonos Oncology plans to accelerate its Phase 2 glioblastoma trial for dubodencel, also known as DOC1021. Additionally, the company aims to expand its clinical portfolio to include other indications, such as refractory melanoma. This financing round follows a successful $11.4 million seed financing from the previous year and acts as a bridge to a Series A financing expected to launch later this year.
Led by CEO Mike Wicks and President/COO Jay Hartenbach, Diakonos Oncology is committed to advancing cancer immunotherapy through its proprietary double-loaded, patient-derived dendritic cell therapeutic platform. Dubodencel, or DOC1021, is a groundbreaking first-in-class autologous dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. This innovative immunotherapy is created using a patient’s dendritic cells combined with mRNA and proteins sourced from freshly obtained tumor specimens.
In conclusion, Diakonos Oncology Corp.’s recent funding success marks a significant milestone in the development of cutting-edge cancer immunotherapies. With a focus on addressing the critical need for effective treatments for late-stage and aggressive cancers, the company’s pioneering approach holds promise for patients facing challenging diagnoses.
